Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A real world study of inotuzumab ozogamicin for the treatment of B-cell acute lymphoblastic leukemia: Multi-center result from SH-ALL group

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYuchen YanLLLigen LiuPLPing Li

Discussion

Loading...

Member takes

Overview

Real-world study demonstrates effective treatment of B-ALL with inotuzumab ozogamicin and venetoclax, indicating good outcomes and acceptable safety profiles.

Key Points

  • This research aims to evaluate the efficacy and safety of inotuzumab ozogamicin for treating B-cell acute lymphoblastic leukemia in a real-world setting.
  • Analyzed outcomes of adult B-ALL patients receiving INO-based therapy across 8 centers
  • Monitored minimal residual disease (MRD) and adverse events using multiparameter flow cytometry
  • Compared treatment outcomes between Ph positive and Ph negative subgroups
  • CR rate reached 100% for newly diagnosed patients treated with INO+VEN
  • Among relapsed/refractory patients, 80.2% achieved complete response (CR)
  • MRD negative rate was 77.8% in patients who achieved CR, with no significant differences between Ph positive and Ph negative groups

Cite This Study

Yan et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2c5https://doi.org/10.1182/blood-2025-6830
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A retrospective analysis of inotuzumab ozogamicin usage in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia2025 · 1 citations
  2. 2Fixed-dose inotuzumab ozogamicin combined with vincristine and prednisone regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia2025
  3. 3INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US2025
  4. 4A real-world multi-institution experience of standard vs alternative dosing of inotuzumab ozogamicin for Relapsed/Refractory pediatric B-cell acute lymphoblastic leukemia2025
  5. 5The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study2025 · 2 citations